We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Syros

News List

Syros acquires clinical-stage drug candidate for acute promyelocytic leukemia pharmaceutical-business-review
December 09, 2020
Syros Pharmaceuticals announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO).
Syros Announces Board of Directors Appointment americanpharmaceuticalreview
December 24, 2019
Syros Pharmaceuticals announced the appointment of Mark Alles to the Company’s Board of Directors.
GBT and Syros team up on new therapies for blood disorders pharmaceutical-technology
December 23, 2019
Global Blood Therapeutics (GBT) has signed an agreement with Syros Pharmaceuticals for the discovery, development and commercialisation of therapies to treat two blood disorders.
Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer biospace
April 17, 2018
Syros Pharmaceuticals today announced new preclinical data showing that SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 trial in patients with advanced solid tumors, demonstrated potent anti-tumor activit